Chief Scientific Officer · Mirati Therapeutics, Inc. (MRTX)

James Christensen

A named executive officer of Mirati Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$5,008,064

Salary $532,308Stock awards $1,907,772

FY2021: $11,548,796

4th of 6 named executive officers at Mirati Therapeutics by FY2022 total.

6 named officers on file for Mirati Therapeutics, FY2022

James Christensen’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • MRTX’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mirati Therapeutics’s whole pay program stands against its peers

  • Mirati Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2023 (DEF 14A).

Free

Get James Christensen’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

James Christensen compensation by year

Mirati Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Mirati Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$500,000$515,000$532,308
Bonus$0$0$0
Stock awards$3,788,750$9,258,049$1,907,772
Option awards$2,379,745$1,506,322$1,336,869
Non-equity incentive$303,750$254,925$1,215,865
Pension and deferred compensation$0$0$0
All other$16,301$14,500$15,250
Total$6,988,546$11,548,796$5,008,064

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirati Therapeutics, Inc. DEF 14A filed April 6, 2023, accession 0001628280-23-011004, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mirati Therapeutics, Inc. filed document, accession 0001628280-23-011004. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2023.

$7.0M
$11.5M
$5.0M
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU19,149$867,641—
PSU16,050$727,226—
RSU14,362$650,742—
RSU10,755$487,309—
RSU7,812$353,962—
RSU5,267$238,648—
RSU2,500$113,275—
Option17,821—$124.31
Option5,718—$214.47
Option8,463—$113.20
Option1,250—$64.14

Per the Outstanding Equity Awards at Fiscal Year-End table in Mirati Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Mirati Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
David MeekChief Executive Officer$11,937,371
Charles BaumPresident, Founder, Head of R&D$7,420,213
Laurie StelzerChief Financial Officer$5,796,064
James Christensen · this pageChief Scientific Officer$5,008,064
Alan SandlerChief Medical Officer$4,793,850
Vickie ReedFormer Chief Accounting Officer$2,038,354

The full Mirati Therapeutics compensation record

free company brief

This page is one person within Mirati Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mirati Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirati Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Christensen's compensation dossier · One-time report. No refunds.